What's behind Monopar Therapeutics's latest stock pullback?
Monopar Therapeutics Inc. (MNPR) dropped 4.8% today as technical overbought conditions triggered heavy intraday selling pressure. The pullback is supported by the stock's proximity to major resistance at $118.38, with the move testing underlying momentum after a broad run above all key moving averages.
Highlights
- Monopar Therapeutics stock trades above all short-, medium-, and long-term moving averages, showing sustained bullish momentum.
- Overbought technical signals are widespread, with the stock down 4.8% to $118.285 and trading near the session low after a downside gap.
- Projected five-session range is $109.81 to $126.76, with an 80% probability of an upward move and resistance at $118.38.
Bullish momentum evident as price tests overbought levels
Monopar Therapeutics is trading above all key moving averages: MA-20 ($114.1723), MA-50 ($98.7343), and MA-200 ($73.2476). This alignment signals ongoing bullish momentum across short-, medium-, and long-term time frames, with the MA-50 versus MA-200 setup also confirming a bullish trend structure. The immediate technical ceiling is at $118.38, while the near-term floor sits at $114.1723. The Ichimoku Kijun at $111.375 is positioned as underlying support beneath both the price and moving averages. Momentum remains robust, with both the Moving Average Convergence Divergence (MACD) and Average Directional Index (ADX) indicating strong buying pressure. The Relative Strength Index (RSI) is elevated at 66.565, with Stochastic RSI at 94.2482 and Commodity Channel Index (CCI) at 132.3842, all pointing to overbought conditions. Bull/Bear Power (BBP) at 8.2105 confirms buyers are firmly in control, accompanied by an overbought warning. The Awesome Oscillator (AO) is neutral. The stock is down to $118.285, slipping 4.8% today after opening with a downside gap of about $1.65, or 1.33%. The current price is near the session low, and intraday volatility stands at 3.56%. Early pressure after the open aligns with overbought signals, suggesting intraday fatigue among buyers.
Earlier, analysts noted that Monopar Therapeutics was sustaining strong bullish momentum but faced overbought technical conditions that could trigger a period of consolidation. The latest session’s intraday pullback amid elevated volatility reinforces these signals, highlighting $118.38 as a critical breakout level for potential renewed upside in the days ahead.